title: Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
authors.affiliation: University of Cincinnati, Co-Chair of the Scientific Committee, 3333 Burnet Av, Cincinnati 45229, United States. rino rappuoli@chiron.com
authors.forename: Rino
authors.initials: R
authors.lastname: Rappuoli
authors.forename: Mariagrazia
authors.initials: M
authors.lastname: Pizza
authors.forename: Steven
authors.initials: S
authors.lastname: Black
authors.forename: E Richard
authors.initials: ER
authors.lastname: Moxon
mesh_terms: D035843:Biomedical Research / Q000266:history / Q000639:trends; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000266:history / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology* / Q000472:pathogenicity*
chemical_list: D022401:Meningococcal Vaccines